Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat.
Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat. The tests were carried out at four dose levels corresponding to the clinically recommended doses and to 1/4, 1/2, and 3/4 of the latter. The drugs were administered orally. Co-trimazine was found to have a greater antibacterial activity than co-trimoxazole and its use at a lower dosage than that of the latter appears warranted.
D000818:Animals; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004927:Escherichia coli Infections / Q000188:drug therapy; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae; D011704:Pyelonephritis / Q000188:drug therapy*; D051381:Rats; D013411:Sulfadiazine / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*
D004338:Drug Combinations; D013449:Sulfonamides; D013411:Sulfadiazine; D014295:Trimethoprim; D013420:Sulfamethoxazole